Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478202 · ClinicalTrials.gov registry record · NA
GOLO Open-Label Pilot 1
A NA study of Diabetes Mellitus Type II, sponsored by Golo.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT03478202: Completed NA study of Diabetes Mellitus Type II, sponsored by Golo.
NCT03478202 is a NA study of Diabetes Mellitus Type II that has completed, run by Golo. The registered enrollment target is 27 participants, below the 236-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03478202, a NA study of Diabetes Mellitus Type II, has completed, sponsored by Golo.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this open-label pilot study is to evaluate the effect of the commercially available GOLO for Life (GFL) weight management program on body weight in a type 2 diabetic patient population after approximately 3 months.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT GOLO RELEASE
Study Locations (1)
Indiana
- Buynak Clinical Research - Valparaiso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2017-12-23 |
| Phase | NA |
What the finished NCT03478202 record still lists
NCT03478202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 236-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Diabetes Mellitus Type II appearing as the primary indexed condition, and to 1 intervention - of which GOLO RELEASE is the first listed.
NCT03478202 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03478202 about?
NCT03478202 is a clinical study titled "GOLO Open-Label Pilot 1". The objective of this open-label pilot study is to evaluate the effect of the commercially available GOLO for Life (GFL) weight management program on body weight in a type 2 diabetic patient population after approximately 3 months.
What is the current status of trial NCT03478202?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-08-01. Estimated completion is 2017-12-23.
What conditions does trial NCT03478202 study?
This clinical trial studies the following conditions: Diabetes Mellitus Type II.
What interventions are being tested in trial NCT03478202?
The interventions under investigation include: GOLO RELEASE (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03478202?
This trial is sponsored by Golo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478202 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus Type II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
RECRUITING · NA
-
TARDIS - Photo Elicitation and Intervention
COMPLETED · NA
-
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana
ACTIVE NOT RECRUITING
-
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
COMPLETED · Phase 4
-
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI